Pharmacological aspects of neuro-immune interactions
dc.creator | Tarasov V.V. | |
dc.creator | Kudryashov N.V. | |
dc.creator | Chubarev V.N. | |
dc.creator | Kalinina T.S. | |
dc.creator | Barreto G.E. | |
dc.creator | Ashraf G.M. | |
dc.creator | Aliev G. | |
dc.date.accessioned | 2020-09-02T22:29:14Z | |
dc.date.accessioned | 2022-11-08T20:18:19Z | |
dc.date.available | 2020-09-02T22:29:14Z | |
dc.date.available | 2022-11-08T20:18:19Z | |
dc.date.created | 2020-09-02T22:29:14Z | |
dc.date.issued | 2018 | |
dc.identifier | 24, 1, 15-21 | |
dc.identifier | 13816128 | |
dc.identifier | https://hdl.handle.net/20.500.12728/6378 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5142660 | |
dc.language | en | |
dc.publisher | Bentham Science Publishers B.V. | |
dc.subject | Amantadine | |
dc.subject | Amitriptyline | |
dc.subject | Interferon | |
dc.subject | Neuro-immune interaction | |
dc.subject | Neurogenesis | |
dc.subject | Oseltamivir | |
dc.subject | Panavir | |
dc.subject | Semax | |
dc.subject | alpha interferon | |
dc.subject | amantadine | |
dc.subject | amitriptyline | |
dc.subject | antivirus agent | |
dc.subject | cytokine | |
dc.subject | immunomodulating agent | |
dc.subject | oseltamivir | |
dc.subject | panavir | |
dc.subject | peptide derivative | |
dc.subject | psychotropic agent | |
dc.subject | semax | |
dc.subject | unclassified drug | |
dc.subject | oseltamivir | |
dc.subject | probucol | |
dc.subject | antiviral activity | |
dc.subject | behavior disorder | |
dc.subject | brain nerve cell | |
dc.subject | cell survival | |
dc.subject | clinical pharmacology | |
dc.subject | delirium | |
dc.subject | depression | |
dc.subject | drug activity | |
dc.subject | drug analysis | |
dc.subject | drug approval | |
dc.subject | drug design | |
dc.subject | drug efficacy | |
dc.subject | drug indication | |
dc.subject | drug mechanism | |
dc.subject | drug safety | |
dc.subject | human | |
dc.subject | immune system | |
dc.subject | immunomodulation | |
dc.subject | inflammation | |
dc.subject | nervous system development | |
dc.subject | neuroprotection | |
dc.subject | nonhuman | |
dc.subject | Parkinson disease | |
dc.subject | perception disorder | |
dc.subject | priority journal | |
dc.subject | Review | |
dc.subject | side effect | |
dc.subject | suicide | |
dc.subject | animal | |
dc.subject | drug effect | |
dc.subject | immunology | |
dc.subject | immunomodulation | |
dc.subject | nervous system | |
dc.subject | Animals | |
dc.subject | Antiviral Agents | |
dc.subject | Humans | |
dc.subject | Immune System | |
dc.subject | Immunomodulation | |
dc.subject | Nervous System | |
dc.subject | Oseltamivir | |
dc.subject | Probucol | |
dc.title | Pharmacological aspects of neuro-immune interactions | |
dc.type | Review |